The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ERIC 2018 | Opinion on MRD in CLL: routine use or clinical trials?
Measurable residual disease (MRD) is moving into the clinical setting, attracting varying opinions on the method and setting of its use. Here. Kanti Rai, MD, of the Feinstein Institute of Medical Research, Manhasset, NY, discusses his thoughts on the impact and use of MRD in the chronic lymphocytic leukemia (CLL) space. This interview recorded at the European Research Initiative on CLL (ERIC) International Meeting 2018, held in Barcelona, Spain.
